Study #2020-0103
An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of CEVOSTAMAB (BFCR4350A) In Patients With Relapsed Or Refractory Multiple Myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
Cevostamab, Tocilizumab
Description
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Multiple Myeloma
Study phase:
Phase I
Physician name:
Sheeba Thomas
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-855-625-0962
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.